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ABSTRACT
Post-transcriptional regulation is a powerful mediator of gene expression, and 
can rapidly alter the expression of numerous transcripts involved in tumorigenesis. 
We have previously shown that the mRNA-binding protein HuR (ELAVL1) is elevated 
in human pancreatic ductal adenocarcinoma (PDA) specimens compared to normal 
pancreatic tissues, and its cytoplasmic localization is associated with increased 
tumor stage. To gain a better insight into HuR’s role in PDA biology and to assess 
it as a candidate therapeutic target, we altered HuR expression in PDA cell lines 
and characterized the resulting phenotype in preclinical models. HuR silencing by 
short hairpin and small interfering RNAs significantly decreased cell proliferation 
and anchorage-independent growth, as well as impaired migration and invasion. 
In comparison, HuR overexpression increased migration and invasion, but had 
no significant effects on cell proliferation and anchorage-independent growth. 
Importantly, two distinct targeted approaches to HuR silencing showed marked 
impairment in tumor growth in mouse xenografts. NanoString nCounter® analyses 
demonstrated that HuR regulates core biological processes, highlighting that HuR 
inhibition likely thwarts PDA viability through post-transcriptional regulation of 
diverse signaling pathways (e.g. cell cycle, apoptosis, DNA repair). Taken together, 
our study suggests that targeted inhibition of HuR may be a novel, promising approach 
to the treatment of PDA.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is currently 
the fourth most common cause of cancer-related death 
in the United States, yet will likely become the second 
leading cause of cancer-related death by 2020, behind 
only non-small cell lung cancer [1]. The development of 
effective therapies achieved for other common cancers 
(e.g. breast, prostate, colorectal) has so far eluded PDA, 
despite the vastly improved understanding of underlying 
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genetic alterations (e.g. KRAS, p16/CDKN2A, TP53) and 
dysregulated signaling pathways involved in pancreatic 
tumorigenesis [2–5]. In fact, since the introduction in 1997 
of gemcitabine (2′,2′-difluorodeoxycytidine) monotherapy 
as the standard of care for metastatic PDA, the only new 
treatment regimens to show superior efficacy (gemcitabine 
+ erlotinib, gemcitabine + Abraxane, and FOLFIRINOX) 
have improved overall survival in the metastatic setting 
by only 0.4–4.3 months [2, 6]. New approaches in the 
treatment of this deadly disease are urgently needed [7].
Genetic mutations and copy number changes can 
dramatically influence gene expression, but they emerge 
in cancer cells over many years of biologic selection [8]. 
Molecular pathway changes at the RNA level represent a 
separate, but understudied, aspect of cancer biology that 
is especially relevant for adaptive cellular reprogramming 
to acute stress [9]. RNA expression changes are rapid, 
efficient, and reversible [9–11]. Broadly speaking, these 
changes may be classified as transcriptional and impact 
the quantity of RNA made by a cancer cell, or post-
transcriptional and affect other aspects of RNA regulation 
(e.g. stability, translation). Post-transcriptional regulation 
is predominantly mediated by trans-acting microRNAs 
(miRNAs) and RNA-binding proteins (RBPs), many of 
which have become implicated in cancer progression 
[12–15]. While miRNAs have received greater attention 
in recent years, RBPs may be even more important for the 
tumorigenesis process [16–18]. RBPs are more stable and 
require a greater investment of cell energy for synthesis; 
moreover, roughly 5% of all genes are believed to encode 
RBPs [19].
Human antigen R (HuR, encoded by the ELAVL1 
gene) is a ubiquitously expressed RBP whose role in 
cancer has become increasingly evident in recent years 
[20]. HuR is primarily localized to the nucleus, where it is 
involved in pre-messenger RNA (mRNA) processing, but 
can shuttle to the cytoplasm where it regulates the stability 
and/or translation of bound mRNA transcripts [21]. 
HuR targets have characteristic AU-rich RNA elements 
(AREs), which are typically located in the 3′ untranslated 
region (3′ UTR). Many of these transcripts are involved 
in key cellular processes such as proliferation, survival, 
angiogenesis, immune response, and metastasis, enabling 
HuR to influence multiple critical survival mechanisms 
[20–22].
No somatic ELAVL1 mutations, copy number 
changes, or epigenetic alterations in any human cancer 
have been reported to date [23, 24]. Yet clinically, we and 
others have demonstrated that total and/or cytoplasmic 
HuR expression is elevated in numerous tissue-specific 
cancers, compared to normal cells [23, 25–30]. In 
general, elevated HuR expression and/or localization 
in the cytoplasm (where HuR carries out the majority 
of its mRNA-regulating functions) are associated with 
poor clinicopathologic features, suggesting that HuR is 
a potent promoter of tumorigenesis or aggressive cancer 
biology [23, 25–29, 31–52]. Specifically in PDA, we have 
shown that HuR expression (both total and cytoplasmic) is 
elevated compared to normal pancreatic tissues, and that 
cytoplasmic HuR expression positively correlates with 
tumor (T) stage [25, 30]. We have also demonstrated using 
in vitro models that HuR protects PDA cells from stressors 
that are relevant to the tumor microenvironment, such as 
glucose withdrawal, hypoxia, and DNA damage (Blanco 
et al., unpublished) [53, 54]. These stressors act as stimuli 
to translocate HuR to the cytoplasm, wherein it stabilizes 
and promotes the translation of target mRNA transcripts 
(e.g. mediators of glucose metabolism, the hypoxia-
inducible proto-oncogene PIM1, the mitotic kinase 
inhibitor WEE1) in a manner that promotes cell survival.
The differential expression of HuR between 
neoplastic and normal tissues (i.e. a more available target 
in cancer cells vs. normal cells), combined with HuR’s 
induction of numerous pro-tumorigenic transcripts over 
multiple defined PDA core signaling pathways, supports 
the hypothesis that HuR is a promising, novel therapeutic 
target in PDA [3, 20]. In fact, several publications have 
explored the effect of modulating HuR expression in 
various tissue-specific cancers (e.g. breast, colorectal, 
brain) [23, 55–57]. In the majority of cases, overexpression 
of HuR enhances tumor proliferation, whereas silencing of 
HuR reduces tumor proliferation. Therefore, we launched 
into a line of investigation utilizing preclinical models 
to test the hypothesis that HuR drives aggressive PDA 
biology, and may be targeted as a novel treatment strategy 
for PDA.
RESULTS
Characterization of doxycycline  
(DOX)-inducible MIA PaCa-2 cell lines
In order to study the effect of HuR expression 
on PDA phenotype, we generated DOX-inducible 
MIA PaCa-2 cell lines. Two cell lines generated by 
lentiviral transduction express distinct short hairpin 
RNAs (shRNAs) that target HuR mRNA, in response to 
DOX treatment (hereafter referred to as Mia.sh290 and 
Mia.sh700, based on the locations of targeted sequences). 
In DOX-treated Mia.sh290 and Mia.sh700 cells, we 
observed significant knockdown of HuR at both mRNA 
and protein levels. The mRNA knockdown in response 
to DOX was 59% and 48% in Mia.sh290 and Mia.sh700, 
respectively (p < 0.001) (Fig. 1A). The protein knockdown 
reached a maximum of 50–60% in both cell lines at 5 days 
of DOX treatment, and was sustained thereafter (Figs. 
1B and S1). HuR expression in a control cell line, stably 
transduced with empty vector lentivirus (hereafter referred 
to as Mia.CTRL), was unaffected by DOX treatment.
Another cell line (hereafter referred to as Mia.HuR) 
was generated by stable transfection with a tetracycline-
responsive plasmid, and overexpressed HuR in response 
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to DOX treatment, with 5.6-fold overexpression at the 
mRNA level (p < 0.0001) and 1.5–2-fold overexpression 
at the protein level (Fig. 1). HuR expression in a control 
cell line, stably transfected with empty vector (hereafter 
referred to as Mia.EV), was unaffected by DOX treatment.
HuR is required for short-term proliferation 
of PDA cells
We first studied the effect of manipulating HuR 
expression on cell proliferation. DOX treatment caused 
a significant decrease in the proliferation of Mia.sh290 
and Mia.sh700 cells over a 10-day period, as assessed by 
PicoGreen staining of double-stranded DNA (dsDNA) 
content (Fig. 2). The decrease did not become apparent 
until 5–6 days of treatment, likely due to the fact that 
DOX-induced HuR silencing is gradual and does not 
reach maximal protein-level knockdown until 4–5 days 
of treatment (Fig. S1). To confirm that the effect of HuR 
manipulation was not cell line-specific, we performed 
transient transfections in an additional PDA cell line (PL5). 
In contrast to the gradual effect of DOX treatment in Mia.
sh290 and Mia.sh700 cells, rapid HuR silencing in PL5 cells 
by small interfering RNA (siRNA) transfection resulted 
in immediate and potent suppression of cell proliferation 
(Fig. S2). Surprisingly, HuR overexpression had no 
apparent effect on cell proliferation, in both the DOX-
treated Mia.HuR cells and PL5 cells transiently transfected 
with HuR overexpression plasmid (Figs. 2 and S2).
HuR is required for anchorage-independent 
growth of PDA cells
There was a possibility that the full effect of 
manipulating HuR expression on PDA proliferation 
could not be appreciated in the short timescale of the 
above experiment. As such, we performed soft agar 
colony formation assays with the DOX-inducible MIA 
PaCa-2 cell lines to gauge anchorage-independent growth 
over a 4 week period (Fig. 3). Cells were seeded in soft 
agar, and cultured in the presence or absence of DOX 
for 4 weeks. In the Mia.sh290 and Mia.sh700 cell lines, 
DOX-induced HuR silencing resulted in 57% and 71% 
decrease in colony number, compared to the untreated 
condition (p < 0.001 and p < 0.05, respectively). As with 
the short-term proliferation assay, DOX treatment had 
no effect on colony formation for the Mia.CTRL, Mia.
EV, and Mia.HuR cell lines. Taken together, these results 
Figure 1: Characterization of DOX-inducible MIA PaCa-2 cell lines. A. qPCR analysis of HuR mRNA expression in Mia.
CTRL, Mia.sh290, and Mia.sh700 cells treated with 0 or 2 μg/ml DOX for 5 days (left), and Mia.EV and Mia.HuR cells treated with 0 or 
2 μg/ml DOX for 2 days (right), normalized to 18S rRNA expression. Mia.sh290 and Mia.sh700 are inducible HuR-silencing cell lines, 
whereas Mia.HuR is an inducible HuR-overexpressing cell line. Mia.CTRL and Mia.EV are the respective control cell lines. B. Western 
blotting analysis of HuR protein expression in Mia.CTRL, Mia.sh290, and Mia.sh700 cells treated with 0 or 2 μg/ml DOX for 5 days 
(left), and Mia.EV and Mia.HuR cells treated with 0 or 2 μg/ml DOX for 2 days (right), normalized to alpha-tubulin protein expression. 
ns = non-significant; *** = p < 0.001; **** = p < 0.0001.
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demonstrate that inhibition of endogenous HuR expression 
compromises the normal proliferation of PDA; however, 
further increases in HuR expression beyond endogenous 
levels do not enhance cell proliferation.
HuR facilitates PDA invasiveness
We next investigated the importance of HuR 
expression on the invasive phenotype of PDA using two 
different assays. In vitro scratch assays with Mia.sh290 
and Mia.sh700 cells pre-treated with 0 or 2 μg/ml DOX 
showed a significant decrease in migration rate under 
HuR-silenced conditions (p < 0.05) (Fig. 4). As expected, 
Mia.CTRL and Mia.EV cells were not significantly 
affected by DOX treatment. Whereas it did not affect 
proliferation of PDA cells, HuR overexpression by DOX 
treatment of Mia.HuR cells significantly increased the 
migration rate (p < 0.05).
To complement the in vitro scratch assays, we 
performed Matrigel invasion assays, which showed the 
same trends (Fig. 5). Cells in serum-free medium were 
seeded on transwell inserts coated with Matrigel, and 
incubated for 24 hours with serum-rich medium in the 
bottom chambers serving as chemoattractant to promote 
invasion. In response to DOX-induced HuR silencing, 
invasion through Matrigel was significantly decreased in 
Mia.sh290 and Mia.sh700 cells (41% decrease and 56% 
decrease, respectively, p < 0.05). Invasion was increased 
with DOX-induced HuR overexpression in Mia.HuR 
cells (13.5-fold increase, p < 0.05), and unchanged in the 
control cell lines (Mia.CTRL and Mia.EV).
The results of both assays were reproduced in PL5 
cells with transient knockdown or overexpression of 
HuR (Fig. S3). In vitro scratch assays showed a decrease 
in migration with HuR silencing, and an increase in 
migration with HuR overexpression (p < 0.01 for both). 
In Matrigel invasion assays, HuR silencing reduced 
invasion by 59% (p < 0.01), and HuR overexpression 
increased invasion 1.7-fold (p < 0.05). Taken together, 
these results demonstrate that both increases and decreases 
in HuR expression affect the invasive phenotype of PDA 
cells. This is in contrast to cell proliferation, where HuR 
overexpression had no effect.
Lipidoid-delivered HuR siRNA suppresses 
established PDA xenograft growth
To test whether or not inhibition of HuR is a 
viable strategy to inhibit PDA growth in vivo, we 
performed a pilot experiment utilizing nude female mice 
subcutaneously injected in their hind flanks with MIA 
PaCa-2. At ~4 weeks post-injection, baseline tumor 
volumes were determined, and mice were randomly 
assigned to 3 groups for treatment with phosphate buffered 
saline (PBS) vehicle, firefly luciferase siRNA (siLuc), or 
HuR siRNA (siHuR). For intratumoral injection, siLuc 
and siHuR were encapsulated in the lipidoid nanoparticle 
98N12-5, which has been previously shown to effectively 
deliver claudin-3 siRNA in an ovarian cancer xenograft 
model [58]. Mice were treated twice per week for 2 weeks, 
and tumor volumes were measured at the indicated time 
points (Fig. 6A). By day 8 of treatment, tumors in the 
siHuR treatment group were significantly smaller than 
tumors in either the PBS or siLuc treatment groups 
(p < 0.05). At the end of the pilot experiment (day 17), 
tumors in the siHuR group were 2-fold smaller than 
tumors in the PBS (p < 0.05) or siLuc (p < 0.01) groups 
(Fig. 6B). Western blotting of tumor lysates harvested at 
Figure 2: HuR is required for short-term proliferation of PDA cells. Relative proliferation of DOX-inducible MIA PaCa-2 cell 
lines treated with 0 or 2 μg/ml DOX for the indicated time points, as determined by measurement of dsDNA content by PicoGreen staining. 
Each data point represents the mean of 5 independent experiments ± standard error of the mean (SEM). * = p < 0.05.
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Figure 3: HuR is required for anchorage-independent growth of PDA cells. A. Representative images of crystal violet-stained 
colonies of DOX-inducible MIA PaCa-2 cell lines cultured in 0 or 2 μg/ml DOX for 4 weeks. Left side shows the original images. Right 
side shows the images processed in ImageJ for clarity and colony counts. B. Relative quantification of colony counts. Each bar represents 
the mean of 3 independent experiments ± SEM. ns = non-significant, * = p < 0.05; *** = p < 0.001.
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the end of the experiment validated HuR silencing in the 
siHuR treatment group (Fig. 6C).
Induced HuR silencing suppresses PDA 
xenograft growth
Based on the result of our pilot experiment, we 
proceeded to test the effect of HuR inhibition on in vivo 
tumor growth utilizing one of our DOX-inducible 
HuR knockdown cell lines (Mia.sh290). We reasoned 
that this model would allow for more consistent and 
long-term inhibition of HuR in the tumors, compared 
to intratumoral injections of siRNA. Nude female 
mice were subcutaneously injected in their hind flanks 
with Mia.sh290 or Mia.CTRL cells. Half of the mice 
in each group were maintained on a DOX diet, and 
Figure 4: HuR promotes PDA migration. A. Representative images of in vitro scratch assays performed with DOX-inducible MIA 
PaCa-2 cell lines pre-treated with 0 or 2 μg/ml DOX for 5 days. Images were taken at 0 h and 48 h post-scratch for the Mia.CTRL, Mia.
sh290, and Mia.sh700 cell lines, and at 0 h and 24 h post-scratch for the Mia.EV and Mia.HuR cell lines. B. Quantification of the rate of 
scratch closure, as measured by change in wound size relative to the 0 h time point. Each data point represents the mean of 3 independent 
experiments ± SEM. * = p < 0.05.
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Figure 5: HuR promotes PDA invasion through an extracellular matrix analogue. A. Representative images of Matrigel 
invasion assays performed with DOX-inducible MIA PaCa-2 cell lines pre-treated with 0 or 2 μg/ml DOX for 5 days. Cells that invaded 
through the Matrigel and onto the basal surface of transwell inserts were stained with Differential Quik and photographed at 20X 
magnification. B. Quantification of Matrigel invasion assays. Values for each cell line were normalized to the number of cells in the 
untreated condition. Each bar represents the mean of 3 independent experiments ± SEM. ns = non-significant; * = p < 0.05.
Figure 6: Lipidoid-delivered HuR siRNA suppresses established PDA xenograft growth. A. Tumor volumes of MIA PaCa-2 
xenografts that were allowed to grow to baseline size of ~100 mm3, then treated with PBS, siLuc, or siHuR for 17 days. Each data point 
represents the mean ± SEM (n = 6 per group). B. Plot of all tumor volumes on day 17 of treatment. Horizontal bars represent the median 
tumor volumes. C. Representative western blot of HuR protein expression in tumors harvested on day 17 of treatment. Beta-actin was used 
as normalization control. * = p < 0.05; ** = p < 0.01.
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tumor volumes were measured three times per week. 
By the end of the experiment, the effect of DOX diet 
on the Mia.sh290 xenografts was profound, with 
3-fold decrease in median tumor volume compared 
to xenografts in mice fed normal diet (623 mm3 vs. 
212 mm3, p < 0.01) (Fig. 7A–7C). In contrast, DOX 
diet had no effect on tumor growth in the Mia.CTRL 
xenografts (Fig. S4).
Figure 7: Induced HuR silencing suppresses PDA xenograft growth. A. Representative images of subcutaneous Mia.sh290 
tumors on the flanks of nude female mice, at the termination of the experiment (day 39). B. Tumor growth curves of Mia.sh290 xenografts. 
Mice were fed normal diet or 200 mg/kg DOX diet starting on day 0 (date of xenograft injection). Each data point represents the 
mean ± SEM (n = 10 for –DOX group, and n = 8 for +DOX group). C. Plot of all tumor volumes on the final day of the Mia.sh290 
xenograft experiment (day 39). Horizontal bars represent the median tumor volumes. D. Left, qPCR analysis of HuR mRNA expression in 
all Mia.sh290 xenografts harvested on day 39. 18S rRNA was used as normalization control. Data were plotted relative to the mean HuR 
mRNA expression in the –DOX group. Horizontal bars represent the medians. Right, plot of HuR mRNA expression vs. tumor volume 
for all Mia.sh290 tumors. Data were plotted relative to the mean of the –DOX group. E. Left, representative western blot of HuR protein 
expression in Mia.sh290 tumors harvested on day 39. Alpha-tubulin was used as normalization control. Right, quantification of the western 
blot. Each bar represents the mean ± SEM (n = 3 per group). * = p < 0.05; ** = p < 0.01; **** = p < 0.0001.
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In the Mia.sh290 xenografts, mRNA expression 
analysis by quantitative PCR (qPCR) demonstrated 
significant reduction of HuR mRNA in the DOX diet group 
(65% decrease compared to normal diet group, p < 0.0001) 
(Fig. 7D). Notably, we observed a significant correlation 
between tumor volume and HuR mRNA expression. That 
is, the largest tumors tended to have the highest HuR 
expression, whereas the smallest tumors tended to have 
the lowest HuR expression (Spearman rho = 0.5624, 
confidence interval 0.1149–0.8202, p < 0.05). Western 
blotting of tumor lysates validated HuR knockdown at the 
protein level (54% decrease in DOX diet group vs. normal 
diet group, p < 0.05) (Fig. 7E). Taken together, the two 
distinct xenograft models of HuR inhibition demonstrate 
that targeted inhibition of HuR may be a viable therapeutic 
strategy against PDA.
HuR regulates multiple cancer-related pathways
In order to better understand the mechanism 
by which HuR inhibition affects PDA phenotype in 
preclinical models, we performed gene expression 
analyses using the nCounter® GX Human Cancer 
Reference Kit (NanoString Technologies, Seattle, WA), 
which allows for high-sensitivity and high-precision 
profiling of 230 genes (plus 6 housekeeping genes) known 
to be differentially expressed in various human cancers 
(see Table S1 for the full list of genes in the panel) [59]. 
Two separate experiments were performed. In the first 
experiment, MIA PaCa-2 cells were transiently transfected 
with control siRNA (siCTRL) or HuR siRNA (siHuR) 
for 72 hours, and total RNA samples were isolated and 
analyzed (4 biological replicates each). Multivariate 
statistical analysis of the filtered and normalized dataset 
(containing 157 genes) revealed that the replicates for the 
siHuR group were clearly separated from the replicates 
for the siCTRL group (Figs. 8 and S5 and Table 1). In 
more detail, the principal component analysis (PCA) 
graph is a two-dimensional representation with each 
sample being projected on each axis based on its transcript 
profile (Fig. 8A). The fact that the siHuR samples are 
separated from the siCTRL samples indicates that the 
analyzed transcript profile changes significantly after 
HuR knockdown. In the case of hierarchical clustering 
(HCL) analysis, the dendrogram shows how well samples, 
or clusters of samples, are correlated with each other 
(Fig. 8B). As shown, the siHuR and siCTRL groups 
arranged in two distinct clusters, supporting the results 
of our PCA analysis. Finally, significance analysis of 
microarrays (SAM) was used to identify transcripts with 
significantly different expression after HuR knockdown, 
and found 87 such transcripts (out of 157, or 55%) (Fig. S5 
and Table 1). In the siHuR samples, 43 transcripts (27%) 
were significantly upregulated, and 44 transcripts (28%) 
were significantly downregulated, compared to siCTRL. 
The 5 upregulated transcripts with the greatest fold change 
were TGFB1 (2.46-fold), L1CAM (2.31-fold), MMP1 
(1.83-fold), FGFR3 (1.77-fold), and PTK7 (1.75-fold). 
The 5 downregulated transcripts with the greatest fold 
change were CDK4 (0.56-fold), EPS8 (0.59-fold), NRAS 
(0.61-fold), BRCA2 (0.62-fold), and CHEK1 (0.63-fold). 
These transcripts encompassed those that are regulated by 
HuR directly (i.e. HuR binds to the transcripts and directly 
regulates their stability and/or translation), as well as 
indirectly (i.e. HuR does not bind to the transcripts, but 
their expression is altered as a downstream effect of HuR’s 
direct regulation of other targets).
In order to distinguish the direct and indirect targets 
of HuR, we performed messenger ribonucleoprotein-
immunoprecipitation (mRNP-IP) in MIA PaCa-2 cells to 
isolate mRNA transcripts that were directly bound to HuR 
(2 biological replicates). For comparison, mRNP-IP with 
isotype control immunoglobulin G (IgG) was performed 
(2 biological replicates). Fig. S6 shows the western blot and 
qPCR performed as quality control steps to validate that the 
mRNP-IP was specific and successful. The input samples 
(cytoplasmic lysates) were all positive for HuR protein and 
alpha-tubulin protein, the HuR IP samples were positive for 
HuR protein but not alpha-tubulin protein, and the control 
IgG IP samples were negative for both HuR protein and 
alpha-tubulin protein. qPCR showed that compared to 
RNAs isolated from control IgG mRNP-IP samples, RNAs 
isolated from HuR mRNP-IP samples were significantly 
enriched in the transcript of deoxycytidine kinase (DCK), 
which has been previously demonstrated by our group 
to be a direct binding target of HuR protein [30]. When 
gene expression analysis for these mRNP-IP RNA samples 
was performed using the nCounter® GX Human Cancer 
Reference Kit, we were able to identify 35 transcripts (out 
of 236, or 15%) that were enriched in the HuR mRNP-
IP RNA samples compared to the IgG mRNP-IP RNA 
samples (i.e. direct targets of HuR) (Table S2). The 5 
most enriched transcripts were SFPQ (1,289-fold), BIRC5 
(1,273-fold), TP53 (1,069-fold), CTNNB1 (788-fold), and 
CD44 (758-fold). By cross-referencing these 35 transcripts 
with the 87 aforementioned transcripts, we were able to 
identify a total of 17 transcripts that were both direct targets 
of HuR, and differentially expressed upon HuR silencing 
(9 upregulated and 8 downregulated transcripts in siHuR 
vs. siCTRL) (Table 1). Notably, 31 out of the 35 direct 
targets of HuR were previously independently validated, 
wherein various high-throughput targeting technologies 
(e.g. photoactivatable-ribonucleoside-enhanced 
crosslinking and immunoprecipitation or PAR-CLIP) 
identified the HuR “target-ome” in a modified human 
embryonic kidney (HEK) cell line [60].
Functional annotation enrichment analysis using 
the Database for Annotation, Visualization, and Integrated 
Discovery (DAVID) revealed the biological processes 
that were significantly enriched based on the list of HuR-
regulated transcripts (Table S3). Among the 43 genes 
upregulated with HuR knockdown, the top enriched 
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Figure 8: HuR regulates key cancer-related transcripts. A. PCA of siCTRL and siHuR samples. X-axis = PC1 (variance 
explained: 47.8%), Y-axis = PC2 (variance explained: 16.3%). B. HCL analysis using Pearson correlation as the distance metric.
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Table 1: HuR-regulated transcripts identified by NanoString nCounter® analyses
Upregulated upon  
HuR knockdown Fold change
Downregulated upon 
HuR knockdown Fold change
TGFB1 2.46 Most Significant CDK4 0.56
ERBB2 1.59 ETS1 0.66
DAP3 1.61 CAV1 0.64
JUN 1.31 PIM1 0.84
L1CAM 2.31 HMMR 0.68
TP53 1.22 CHEK1 0.63
FGFR3 1.77 TOP2A 0.72
MTA1 1.19 ERCC4 0.72
PLAUR 1.48 RRM1 0.76
TIMP2 1.34 RB1 0.71
PTK7 1.75 CCNA2 0.67
FGFR4 1.68 TGFBR3 0.84
MYC 1.18 CDC2 0.71
ERCC2 1.25 BIRC5 0.68
YES1 1.26 BRCA2 0.62
MMP1 1.83 NRAS 0.61
IGFBP2 1.65 EPS8 0.59
JUNB 1.48 CDK2 0.69
PCTK1 1.24 ETV6 0.73
CSK 1.16 ETV1 0.77
AREG 1.31 CDK6 0.77
IGFBP6 1.32 DEK 0.75
TIMP1 1.21 CDKN2C 0.70
AKT2 1.20 BRCA1 0.76
RARA 1.18 TFRC 0.86
NOTCH1 1.35 REL 0.80
LIF 1.33 WT1 0.73
SERPINE1 1.17 FANCG 0.89
HIF1A 1.17 CDC25B 0.86
BCR 1.14 NQO1 0.87
CEBPA 1.13 ABL1 0.93
CSF3 1.35 BMI1 0.79
TUBB 1.29 NUMA1 0.89
CCNE1 1.17 STAT1 0.87
TYRO3 1.23 MYBL2 0.86
(Continued )
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biological processes were related to transcriptional 
regulation, nucleotide synthesis, and nucleotide 
metabolism. Among the 44 genes downregulated with 
HuR knockdown, the top enriched biological processes 
were related to cell cycle, cell proliferation, DNA repair, 
and apoptosis. Among the 35 genes whose transcripts 
are directly bound by HuR, the top enriched biological 
processes were related to cell cycle, cell proliferation, 
and apoptosis. Taken together, these results suggest that 
therapeutic targeting of HuR can affect multiple essential 
biological processes at once, by disrupting HuR’s 
regulation of numerous cancer-related transcripts.
DISCUSSION
Despite the discovery of multiple genomic 
alterations that give rise to PDA, attempts to exploit these 
lesions (e.g. oncogenic RAS activation) for either early 
detection or treatment have so far been unsuccessful in 
the clinical setting [2–5, 7, 61]. In order to change the 
paradigm of PDA management for the better, novel 
strategies that venture outside of the traditional “gene-
centric” approach may be necessary. This perspective 
prompted us to investigate a relatively understudied, 
but highly relevant, aspect of cancer biology – post-
transcriptional regulation by RBPs. While others have 
studied the RBP HuR in the context of other cancer 
types, we are the first to study this regulatory protein in 
preclinical models of PDA. The findings from this study 
complement previous studies by our group that cast HuR 
as an intriguing therapeutic target in PDA [25, 53, 54, 62].
In the present study, we demonstrated that 
silencing HuR expression significantly inhibits PDA 
proliferation in vitro (Figs. 2, 3, and S2) and in vivo 
(Figs. 6 and 7). However, in contrast to the majority of 
published results, HuR overexpression did not enhance 
PDA proliferation in our cell culture models (Figs. 2, 3, 
and S2). We speculate that in PDA, HuR’s contribution 
to proliferative potential is maximal (i.e. saturated) at 
baseline expression levels. In fact, too much expression/
activity of HuR has been shown to have detrimental 
effects on cancer cells. For example, Gubin et al. 
demonstrated that exogenous HuR overexpression in 
the MDA-MB-231 triple-negative breast cancer cell 
line enhanced cell proliferation in vitro, but dramatically 
impaired tumor growth in vivo in an orthotopic 
xenograft model [57]. Moreover, although HuR is 
normally a promoter of cell survival, exposure of cells 
to lethal stress (in which cell death is unavoidable) has 
been shown to irreversibly convert HuR into a promoter 
of apoptosis [63]. These observations support the notion 
that HuR’s effect on the cancer phenotype is most likely 
both tissue- and context-dependent. In comparison 
to HuR’s effect on cell proliferation, both HuR 
overexpression and silencing affected PDA invasiveness 
in in vitro experiments (Figs. 4, 5, and S3).
Even though our findings support a strong role for 
HuR in PDA tumorigenesis, the presented data should be 
interpreted in the context of the preclinical models used 
in this study. For instance, the proof-of-principle studies 
described herein were performed in a limited number of 
immortalized, established PDA cell lines. Commercial 
Upregulated upon  
HuR knockdown Fold change
Downregulated upon 
HuR knockdown Fold change
MLH1 1.16 TNFSF10 0.83
BCL2L1 1.29 BRAF 0.88
EGR1 1.35 XRCC5 0.85
GRB7 1.36 CDC25C 0.79
TNFRSF10B 1.06 TOP1 0.82
IFNGR1 1.12 BLM 0.87
IGF1 1.15 MSH2 0.87
CTNNB1 1.09 TFDP1 0.87
Least Significant PCNA 0.84
Full list of transcripts that were upregulated (left) or downregulated (right) in MIA PaCa-2 cells transfected for 72 hours 
with HuR siRNA, compared to cells transfected with control siRNA, with the associated fold changes. All fold changes are 
significant (p < 0.05), with the list of transcripts in each column sorted in the order of significance (most significant at the top; 
least significant at the bottom). Gray cells indicate transcripts that were identified as direct HuR targets (i.e. transcripts that 
were significantly enriched in HuR mRNP-IP samples compared to control IgG mRNP-IP samples, as described in Table S2). 
False discovery rate (FDR) = 0% for all transcripts. 
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cell lines perform robustly under many experimental 
conditions and exhibit hallmark molecular aspects of PDA 
(e.g. KRAS and TP53 mutations), thereby functioning as 
convenient model systems; yet, their generalizability to 
primary and metastatic PDAs in patients is difficult to 
determine [64, 65]. To that end, we are in the process 
of establishing conditionally-reprogrammed cells and 
organoids derived from PDA patient samples, which 
should serve as complementary alternatives to established 
cell lines [66, 67].
Additionally, subcutaneous heterotopic xenografts 
have limitations as an in vivo model for PDA [68]. Tumor 
metastases cannot be properly studied with subcutaneous 
xenografts, and the hallmark desmoplastic reaction 
observed in most human PDAs do not develop in this 
preclinical model [2, 4, 68–70]. Thus, we are currently 
in the long-term process of utilizing an established 
genetically engineered mouse model (GEMM) of 
PDA – KrasLSL-G12D/+; Trp53LSL-R172H/+; Cre (KPC) – as 
a background to manipulate pancreas-specific HuR 
expression (Sawicki et al., unpublished) [71]. In the 
present study, HuR overexpression did not affect the 
growth of established PDA in vitro, in the context of an 
HuR network that is already highly engaged in PDA cell 
lines (Figs. 2, 3, and S2). However, we hypothesize that 
HuR overexpression may cooperate with KRAS and TP53 
mutations to promote pathogenesis from normal cells 
(where HuR activity is typically minimal at baseline) to 
pre-cancerous pancreatic intraepithelial neoplasia (PanIN) 
and eventually PDA. Conversely, we hypothesize that 
crossing a pancreas-specific HuR deletion GEMM with 
KPC GEMM will dramatically retard or even eliminate 
pancreatic tumorigenesis. With the proper controls, these 
GEMMs will provide an ideal setting to study HuR 
within the context of an intact immune system and a more 
relevant tumor microenvironment. In particular, these 
GEMMs will enable studies into HuR’s role in every stage 
of tumor development – from the early stages of tumor 
initiation to the late stages of metastatic invasion.
Consistent with previous mechanistic studies, we 
have demonstrated here that HuR directly and indirectly 
regulates numerous cancer-related transcripts (Fig. 8 
and Table 1). These transcripts play critical roles in 
multiple essential biological processes related to cell 
cycle, DNA repair, apoptosis, and nucleotide metabolism, 
among others, and emphasize the notion that therapeutic 
inhibition of HuR alone can simultaneously affect all of 
these pathways. In fact, previous studies revealed that 
HuR regulates clusters of genes, referred to as regulons, 
in order to efficiently affect whole pathways [72]. In 
light of HuR’s broad influence over diverse critical pro-
survival pathways, HuR inhibition provides a unique 
therapeutic opportunity observed with just a handful of 
master regulators of cancer biology (e.g. MYC) [73]. In 
conventional targeted therapeutic strategies, only one 
gene or one pathway is typically affected at a time. Cancer 
cells rely on intrinsic redundancy in cellular signaling, 
and invoke any number of chemoresistance mechanisms 
to overcome therapies that fit under the umbrella of 
“precision medicine” [74]. In contrast, HuR inhibition 
offers a new global synthetic lethal approach, in which 
multiple core signaling pathways are targeted at once, 
leaving the cancer cells with no viable compensatory 
mechanisms.
To date, the best-characterized small molecule 
inhibitor of HuR is the chrysanthone-like compound 
MS-444 [75]. Despite its success as a lead compound 
in preclinical models, issues with its stability 
and bioavailability in vivo may hinder its clinical 
utility (Blanco et al., unpublished). As such, we have begun 
to explore several alternative strategies for HuR inhibition. 
In the present study, we were able to demonstrate 
effective HuR knockdown and reduction of tumor growth 
utilizing HuR siRNA intratumorally delivered by lipidoid 
nanoparticles (Fig. 6). However, a clinically relevant 
therapy for PDA must have systemic activity in order 
to treat microscopic and macroscopic metastases, which 
typically drive the clinical course of the disease in patients 
[76]. Studies that involve systemic therapeutic strategies 
to inhibit HuR will need to address toxicity and define a 
therapeutic window. It has been previously reported that 
postnatal global deletion of HuR in mice has no apparent 
effect on quiescent stem cells and differentiated cells 
[77]. However, rapidly proliferating progenitor cells 
in the thymus, bone marrow, and intestine underwent 
apoptosis, and the mice eventually died due to atrophy of 
hematopoietic organs and obstructive enterocolitis. This 
suggests that any HuR inhibitor that acts systemically 
may very well, at minimum, be accompanied by toxicities 
similar to those seen with conventional chemotherapeutics 
(e.g. nausea/vomiting/diarrhea, immunosuppression). In 
order to minimize potential systemic toxicities, we are 
currently developing a systemic siRNA-based strategy that 
utilizes a DNA scaffold, which may be functionalized with 
targeting moieties that preferentially direct the siRNA to 
PDA cells.
Although a therapeutic window of opportunity may 
be realized with generalized HuR inhibition due to the fact 
that its regulatory targets are commonly active in cancer-
associated survival pathways (as compared to normal 
cells), we believe that inhibiting HuR’s most critical 
binding interactions may very well improve specificity 
without compromising therapeutic efficacy. This may be 
theoretically accomplished by precisely disrupting the 
interaction between HuR and the specific AREs present on 
selected target transcripts. This approach should mitigate 
the disruption of HuR’s regulation of house-keeping 
transcripts (which contain different AREs) that are 
essential for normal biological processes. Specifically, we 
have begun to develop decoy RNA oligonucleotides that 
contain sequence motifs complementary to the 3′ UTRs 
of cancer-specific HuR binding targets (e.g. WEE1) [54]. 
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These “suicide UTRs,” or “sUTRs,” can theoretically 
compete with HuR for these regulatory binding sites 
(essentially acting as RNA sponges), and thereby 
antagonize HuR-directed pro-survival pathways.
To summarize, we provide proof-of-principle 
evidence that targeted HuR inhibition impairs the 
malignant phenotype of PDA cells in both in vitro and 
in vivo preclinical models. Subsequent translational 
studies, utilizing more clinically relevant model systems, 
will further determine the utility of targeting HuR to treat 
PDA as well as other cancers.
MATERIALS AND METHODS
Cell culture
MIA PaCa-2 human pancreatic ductal 
adenocarcinoma (PDA) cell line was purchased 
from American Type Culture Collection (ATCC, cat. 
#CRL-1420). PL5 human PDA cell line was kindly 
provided by S. E. Kern (Johns Hopkins University, 
Baltimore, MD). Both cell lines were cultured in 
Dulbecco’s modified Eagle medium (DMEM; Life 
Technologies, cat. #11965-084) supplemented with 10% 
Tet System Approved Fetal Bovine Serum (FBS; Clontech 
Laboratories, cat. #631106) and 2 mM L-glutamine 
(Gemini Bio-Products, cat. #400-106). Cells were 
routinely passaged and cultured at 37°C in a humidified 
incubator with 5% CO2.
Generation of doxycycline (DOX)-inducible MIA 
PaCa-2 cell lines
DOX-inducible HuR knockdown cell lines
To generate short hairpin RNA (shRNA)-
expressing plasmids, shRNA-encoding oligonucleotides 
targeting HuR (referred to as sh290 and sh700) were 
cloned into the Tet-pLKO-puro lentiviral plasmid 
(Addgene, cat. #21915) as previously described [78]. 
The targeted sequences were as follows: sh290 = 
sense 5′-GCAGCAUUGGUGAAGUUGAAUCU-3′, 
antisense 5′-AGAUUCAACUUCACCAAUGCUGC-3′; 
sh700 = sense 5′-GCCCAUCACAGUGAAGUUUGCA-3′, 
antisense 5′-UGCAAACUUCACUGUGAUGGGC-3′. 
Lentiviruses were generated and transduced into MIA 
PaCa-2 at multiplicity of infection (MOI) = 1, and 
selection was performed with 1 μg/ml puromycin 
dihydrochloride (Life Technologies, cat. #A11138-03) to 
isolate clones of Mia.CTRL (transduced with empty vector 
lentivirus), Mia.sh290, and Mia.sh700.
DOX-inducible HuR overexpression cell lines
Tet-On 3G Inducible Expression System 
(Clontech Laboratories, cat. #631165) was used 
according to manufacturer’s instructions to generate 
MIA PaCa-2 cells stably transfected with pCMV-Tet3G 
plasmid (Mia.pCMV-Tet3G). HuR complementary 
DNA (cDNA) was cloned into pTRE3G-mCherry 
plasmid using In-Fusion HD Cloning Plus (Clontech 
Laboratories, cat. #638909). Mia.pCMV-Tet3G cells 
were then stably transfected with either empty vector 
(pTRE3G-mCherry) or HuR overexpression vector 
(pTRE3G-mCherry-HuR) to generate Mia.EV and Mia.
HuR cell lines, respectively.
For DOX induction, cells were treated with 
2 μg/ml DOX hyclate (Sigma-Aldrich, cat. #D9891) 
for the indicated times.
DNA and small interfering RNA (siRNA) transfections
For transient HuR overexpression studies, the 
coding region of the human ELAVL1 gene was subcloned 
from pCMV6-XL5 ELAVL1 plasmid (OriGene, cat. 
#SC119271) into pcDNA3.1/Zeo(+) plasmid (Life 
Technologies, cat. #V860–20), and transfected into 
PDA cells. Transfection with empty vector served 
as control. Transient HuR knockdown studies were 
performed by transfecting cells with a custom-made 
HuR siRNA oligonucleotide (GE Dharmacon; sense 
5′-CCAUUAAGGUGUCGUAUGCUCUU-3′, antisense 
5′-UUGAGCAUACGACACCUUAAUGG-3′). 
Transfection with ON-TARGET plus Non-targeting 
Control siRNA (GE Dharmacon, cat. #D-001810-
01-05) was used as negative control. All transfections 
were performed using Lipofectamine 2000 (Life 
Technologies, cat. #11668) according to manufacturer’s 
instructions.
Messenger RNA (mRNA) expression analysis
Total RNA was extracted using TRIzol Reagent 
(Life Technologies, cat. #15596) according to 
manufacturer’s instructions. cDNA was synthesized 
from 1 μg of total RNA using random primers and 
MultiScribe Reverse Transcriptase (Life Technologies, 
cat. #4368813). Quantitative PCR (qPCR) analysis 
was performed using Applied Biosystems 7500 
Fast Real-Time PCR System (Life Technologies, 
cat. #4351107) and SYBR Select Master Mix 
(Life Technologies, cat. #4472908). HuR mRNA 
expression was detected with the following primer 
set: sense 5′-GCTCGGTCTACTCAGGCATC-3′, 
antisense 5′-CCAGTCCAGGAGCCTAATGA-3′. 
18S rRNA expression was used for normalization, 
and was detected with the following primer set: sense 
5′-GTAACCCGTTGAACCCCATT-3′, antisense 
5′-CCATCCAATCGGTAGTAGCG-3′. Relative 
quantification was performed using the 2-ΔΔCt method, as 
previously described [79].
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Western blot analysis
For total protein extraction, cell pellets were 
resuspended in radioimmunoprecipitation assay 
(RIPA) buffer supplemented with 1X protease 
inhibitor cocktail, 1 mM sodium orthovanadate, 
and 2 mM phenylmethanesulfonylfluoride (PMSF) 
(Santa Cruz Biotechnology, cat. #sc-24948). Samples 
were placed on ice for 5 minutes, then centrifuged at 
16,000 × g, at 4°C, for 30 minutes. The supernatants 
were recovered, and protein concentrations were 
determined using Pierce BCA Protein Assay Kit (Life 
Technologies, cat. #23225). The protein samples were 
mixed with Laemmli sample buffer, heated at 95°C for 
10 minutes, then size-fractionated on homemade 10% 
polyacrylamide gels. The samples were then transferred 
to Immun-Blot low fluorescence PVDF membranes 
(Bio-Rad Laboratories, cat. #162–0264) for 2 hours at 
4°C. The membranes were blocked for 1 hour at room 
temperature using Odyssey Blocking Buffer (LI-COR 
Biosciences, cat. #927–40000), then probed overnight 
at 4°C with mouse monoclonal antibodies against HuR 
(Santa Cruz Biotechnology, cat. #sc-5261), alpha-
tubulin (Life Technologies, cat. #32-2500), and/or 
beta-actin (Sigma-Aldrich, cat. #A5441) at dilutions of 
1:2,000, 1:10,000, and 1:5,000, respectively, in Odyssey 
Blocking Buffer supplemented with 0.1% Tween 20 
(Fisher Scientific, cat. #BP337). Following washes 
with TBST, the membranes were incubated for 1 hour 
at room temperature with IRDye 800CW Goat anti-
Mouse Immunoglobulin G (IgG) (LI-COR Biosciences, 
cat. #926–32210) using dilution of 1:20,000 in Odyssey 
Blocking Buffer supplemented with 0.1% Tween 20 and 
0.01% sodium dodecyl sulfate (SDS; Affymetrix, cat. 
#77504). Following washes with TBST, the membranes 
were scanned using Odyssey Infrared Imaging System 
(LI-COR Biosciences, model #9120) for target protein 
detection. Signal quantification was performed using 
Odyssey Infrared Imaging System software.
Cell proliferation assay
Cells were seeded in 96-well culture plates at 
250 cells/well, and allowed to grow for 0–10 days in 
media containing 0 or 2 μg/ml DOX. At each indicated 
time point, cells were rinsed twice with Dulbecco’s 
phosphate buffered saline (DPBS; Life Technologies, 
cat. #14190), and lysed with deionized water. Double-
stranded DNA (dsDNA) was stained by Quant-iT 
PicoGreen dsDNA reagent (Life Technologies, cat. 
#P7581), and fluorescence intensity was measured 
by a microplate reader (Tecan, part #F129015) using 
excitation wavelength of 485 nm and emission 
wavelength of 535 nm. Data were plotted relative to 
day 0 to provide estimates of cell proliferation based on 
dsDNA content.
Soft agar colony formation assay
The experiment was performed as previously 
described, with slight modifications [80]. Briefly, the 
base agarose layer was prepared in 6-well culture plates 
by pouring 2 ml of base agarose mixture comprised of 
1X DMEM, 10% FBS, and 0.5% agarose (Affymetrix, 
cat. #32802). Cells were prepared in top agarose mixture 
comprised of 1X DMEM, 10% FBS, and 0.35% agarose, 
and poured over the solidified base agarose layer at final 
seeding density of 5,000 cells/well. After solidification of 
the top layer, 2 ml of growth media with 0 or 2 μg/ml 
DOX were added to each well, and samples were placed 
in a 37°C incubator. Cells were allowed to incubate for 
4 weeks, with the overlaid media and DOX exchanged 
thrice weekly. At the termination of the experiment, 
samples were rinsed twice with DPBS and fixed with 
3.7% formaldehyde (Sigma-Aldrich, cat. #252549) for 
10 minutes. After two more washes with DPBS, cells 
were stained with 0.01% crystal violet (Santa Cruz 
Biotechnology, cat. #sc-207460) for 1 hour. Photographs 
were taken using EVOS FL Imaging System, and colonies 
were counted using ImageJ (National Institutes of Health, 
Bethesda, MD). To exclude background, only colonies > 
10,000 μm2 were counted.
In vitro scratch assay
Cells were pre-treated with 0 or 2 μg/ml DOX for 
5 days, then seeded in 6-well culture plates and allowed 
to grow to confluence. The cell monolayer was scratched 
in a straight line with a p200 pipet tip, then rinsed twice 
with DPBS to remove debris. Fresh culture medium was 
added, with 2 μg/ml DOX in the appropriate wells. Every 
12 hours, photographs of the scratches were taken using 
EVOS FL Imaging System. The mean width of each 
scratch was measured using ImageJ. Data were plotted 
relative to the 0 hour time point.
Matrigel invasion assay
The experiment was performed as described 
in Corning’s Cell Invasion Assay protocol (available 
online at the following URL: http://csmedia2.corning.
com/LifeSciences/media/pdf/protocol_DL_031_Cell_
Invasion_Assay.pdf). Briefly, permeable supports 
(Corning, cat. #353097) were coated with 200 μg/ml 
Matrigel basement membrane matrix (Corning, cat. 
#354234), and inserted in 24-well companion plates 
(Corning, cat. #353504). Cell suspensions were prepared 
in serum-free DMEM, and seeded in invasion chambers at 
25,000 cells/chamber. DMEM with 20% FBS was added 
to each well as chemoattractant. Samples were incubated 
at 37°C for 24 hours to allow for cell migration through 
the Matrigel. Non-invading cells on the apical surface of 
the Matrigel-coated supports were removed with cotton 
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swabs, and cells that had migrated to the lower surface of 
the supports were stained using Differential Quik Stain Kit 
(Polysciences, cat. #24606). Photographs were taken, and 
cells were counted using ImageJ. Samples were prepared 
in triplicate, and 5 fields were photographed per sample (at 
20X magnification).
Mouse xenografts
Mouse protocols were approved by the Thomas 
Jefferson University Institutional Animal Care and Use 
Committee.
siHuR lipidoid nanoparticle study
We encapsulated siRNAs in the lipidoid nanoparticle 
98N12-5, as previously described [58]. The targeted 
sequences were as follows: firefly luciferase siRNA (siLuc) 
= sense 5′-CUUACGCUGAGUACUUCGA-3′, antisense 
5′-UCGAAGUACUCAGCGUAAG-3′; HuR siRNA 
(siHuR) = sense 5′-GCGUUUAUCCGGUUUGACA-3′, 
antisense 5′-UGUCAAACCGGAUAAACGC-3′. 
Nine 6-week-old, female, athymic nude mice (Harlan 
Laboratories, cat. #6904F) received subcutaneous 
injections of 2 × 106 MIA PaCa-2 cells in both flanks. 
Cells were prepared in 100 μl solution comprised of 
80% DPBS and 20% Matrigel (Corning, cat. #356237). 
Tumors were allowed to grow to mean tumor volume 
of ~100 mm3, whereupon mice were randomly assigned 
to 3 groups. Mice received intratumoral injections 
of 1) PBS; 2) siLuc lipidoid nanoparticle; or 3) siHuR 
lipidoid nanoparticle, following the treatment regimen 
of 25 mg/kg, twice per week for 2 weeks. Tumors were 
measured at the indicated time points using an electronic 
caliper, and tumor volumes were calculated using the 
formula Volume = Length × Width2/2. Upon termination 
of the experiment, mice were euthanized using carbon 
dioxide inhalation followed by cervical dislocation, and 
tumors were harvested.
DOX-inducible HuR knockdown study
6-week-old, female, athymic nude mice received 
subcutaneous injections of 2 × 106 Mia.sh290 cells 
or 1.5 × 106 Mia.CTRL cells in both flanks (10 mice 
per cell line). Cells were prepared in 100 μl solution 
comprised of 80% DPBS and 20% Matrigel. Starting on 
the day of injection, 5 mice were fed 200 mg/kg DOX 
diet (Bio-Serv, cat. #S3888), while the other 5 mice 
were maintained on control diet (Bio-Serv, cat. #S4207). 
Tumors were measured three times per week using an 
electronic caliper, and tumor volumes were calculated 
using the formula Volume = Length × Width2/2. For the 
Mia.sh290 xenografts, the experiment was terminated 
on day 39, when one of the tumors surpassed 1,500 mm3 
(a pre-defined requirement for termination). For the 
Mia.CTRL xenografts, the experiment was terminated 
on day 72, upon clear evidence that DOX diet had no 
significant effect on tumor growth over a prolonged 
time period. Upon termination of the experiment, 
mice were euthanized using carbon dioxide inhalation 
followed by cervical dislocation, and tumors were 
harvested.
Messenger ribonucleoprotein-immunoprecipitation 
(mRNP-IP)
mRNP-IPs were performed as previously 
described [81]. Briefly, MIA PaCa-2 cytoplasmic lysates 
were obtained using CelLytic NuCLEAR Extraction 
Kit (Sigma-Aldrich, cat. #NXTRACT) according to 
manufacturer’s instructions, with the modification of 
supplementing with 100 U/ml RNase inhibitor (Life 
Technologies, cat. #N8080119) to preserve RNA 
integrity. HuR protein and its bound mRNA cargo were 
immunoprecipitated by incubating the cytoplasmic 
lysates with mRNP-IP-grade HuR antibody (MBL 
International Corporation, cat. #RN004P) or isotype 
control IgG (Santa Cruz Biotechnology, cat. #sc-2027) 
pre-coated to Protein A-Sepharose beads (Sigma-Aldrich, 
cat. #P9424). HuR was digested with proteinase K (Life 
Technologies, cat. #AM2546), and the released mRNA 
transcripts were purified with TRIzol Reagent for further 
analysis.
NanoString nCounter® assay, data normalization and 
filtering, multivariate statistical analysis, and pathway 
analysis
For the identification of cancer-related transcripts 
that were differentially expressed between MIA PaCa-
2 cells transfected with control siRNA or HuR siRNA, 
200 ng each of total RNA samples were analyzed with the 
nCounter® GX Human Cancer Reference Kit (NanoString 
Technologies; see Table S1 for the complete gene list) 
according to manufacturer’s protocols [59]. Six positive 
hybridization controls that do not correspond to any 
known transcript sequence were added at fixed amounts 
into each sample. Eight probes served as negative 
controls that were used to estimate the background noise 
(average plus three standard deviations for each sample). 
Transcripts with expression lower than this threshold in 
four or more samples were filtered out of the analysis. The 
remaining 157 transcripts were then normalized based 
on the geometric mean of the positive controls for each 
sample. From the resulting table, the three transcripts 
with the lowest coefficient of variation (CoV) were 
chosen (CoV < 7%): FOSL2, TNFRSF10B, and ABL1. 
These transcripts were flagged as “housekeeping genes,” 
and the values in each sample were further normalized 
based on the consideration that the geometric mean of the 
expressions of these transcripts should remain unchanged 
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across all samples. Transcript expression was also 
standardized before multivariate statistical analysis.
Principal component analysis (PCA), hierarchical 
clustering (HCL; Pearson correlation metric), and 
significance analysis of microarrays (SAM) were 
performed using the TM4-MeV statistical analysis 
software, as previously described [82–84]. Pathway 
enrichment was run using the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID) [85, 
86]. Specifically, enrichment for biological process (BP) 
terms of gene ontology (GO) was sought. The background 
list for the enrichment analysis was the full list of 236 
genes included in the nCounter® GX Human Cancer 
Reference Kit.
For the identification of the cancer-related transcripts 
that HuR directly binds, 200 ng each of HuR and control 
IgG mRNP-IP RNA samples were analyzed with the 
nCounter® GX Human Cancer Reference Kit, as above. 
Data filtering and positive control normalization were 
also performed as described above. To identify binders, 
the average of the normalized counts of the two HuR 
mRNP-IP replicates had to be at least twice the maximum 
of the normalized counts of the two control IgG mRNP-IP 
replicates. Fold enrichment for each binder was calculated 
as the ratio of its average expression in the HuR mRNP-IP 
samples relative to the average signal of the non-binders.
Further details in regards to statistics are available 
upon request.
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